Research
Hormonal
Co-stimulation of GLP-1 with other receptors like GIP and glucagon may provide additional therapeutic benefits.
Practitioners should consider combination therapies involving GLP-1 for enhanced weight loss effects.
StrongSupportsmedium confidence
Potentiation and complementation of GLP-1 effects by co-stimulation of GIP, glucagon, or amylin and other receptors contribute to additional benefits.
Why this rating
The claim is based on the described interactions of GLP-1 with other hormones.
Source
GLP-1-based medications: Mechanisms involved in obesity treatment
Javier Salvador · Medicina Clínica (English Edition) · 2025
DOI 10.1016/j.medcle.2025.107035
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →